Carsten Lu, Adlai Nortye CEO

A No­var­tis castoff with a trou­bled past head­lines Chi­nese biotech's Hong Kong IPO quest

Tak­ing on a failed drug from one of bio­phar­ma’s biggest play­ers and spin­ning it in­to a win­ner is nev­er an easy task. But in the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.